MiNK Therapeutics price to book ratio INKT

Market value divided by the book value of the company's net assets, since 2022.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 10.1×; Mar 2023
Peer median: 1.9×

MiNK Therapeutics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Mar 2023, at 10.1×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	10.1×	10.0×	11.8×
2022	13.1×	1.8×	15.0×

Against its peers

Companies in Healthcare nearest MiNK Therapeutics' size, closest first, today.

Company	Price to book ratio
INKTMiNK Therapeutics	n/m
APTAlpha Pro Tech	0.9×
ATNMActinium Pharmaceuticals	1.6×
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
NEPHNephros	3.2×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	1.3×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on MiNK Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.